Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts
Authors' conclusion
FibroTest® is independently and positively associated with the degree of coronary artery calcification in patients with T2D, suggesting that FibroTest® could be a relevant biomarker of coronary calcification and cardiovascular risk.
Study context
- Population
- Patients with T2D from the DIACART and ACCoDiab cohorts; Coronary artery calcium score (CACS) measured by CTtwo cohorts
- Participants
- 157 vs 460
- Exposure
- Non-alcoholic fatty liver disease (NAFLD) biomarkers vs coronary artery calcium score
- DIACARTn = 157
- ACCoDiabn = 460
- Outcome
- Association of NAFLD biomarkers in FibroMax panels with degree of coronary artery calcification (CACS)
Methodological detailstwo independent cohorts
- Two independent cohorts
Main finding
As reported in the abstract
CACS by FibroTest
- CACS increased with FibroTest stages, DIACART (P for trend)
- 0.0009
- CACS increased with FibroTest stages, ACCoDiab (P for trend)
- 0.0001
- DIACART: FibroTest score vs CACS, univariate r (p = 0.0002)
- 0.293
- DIACART: FibroTest score adjusted for SCORE2-Diabetes risk factors, β ± SE (p = 0.028)
- 941 ± 425
- ACCoDiab: FibroTest F3-F4 stage vs CACS, point-biserial rpbi (p = 0.024)
- 0.104
- ACCoDiab: FibroTest F3-F4 adjusted for SCORE2-Diabetes risk factors, β ± SE (p = 0.016)
- 234 ± 97
Observational data: associations, not effects.
Further findings
Prediction of CACS adding FibroTest to SCORE2-Diabetes risk factors
- Goodness-of-fit multiplied by, DIACART
- 4.1
- Goodness-of-fit multiplied by, ACCoDiab
- 6.7
Other FibroMax panels (SteatoTest, NashTest, ActiTest) and CACS
- No significant relationship with CACS in either cohort
Original publication
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts. Cardiovasc Diabetol. Published 13 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →